Increased cardiovascular risk in HIV-infected patients may relate to arterial inflammation

July 22, 2012

The elevated risk of cardiovascular disease seen in patients infected with HIV appears to be associated with increased inflammation within the arteries, according to a study that will appear in a special issue of JAMA published in conjunction with the International AIDS Conference. The report from Massachusetts General Hospital (MGH) found that levels of inflammation within the aortas of HIV-infected individuals with neither known cardiovascular disease nor elevated traditional risk factors were comparable to those of patients with established cardiovascular disease.

"Several recent studies, including ones that we've done, have found that HIV-infected patients have about twice the and stroke as non-infected individuals do," says Steven Grinspoon, MD, director of the MGH Program in Nutritional and a member of the Neuroendocrine Unit, the study's principal investigator. "These new data suggest a plausible mechanism through which increased arterial inflammation related to activation of the immune system may increase the risk of in these patients."

While traditional – such as accumulation of abdominal fat, smoking, high blood pressure and elevated cholesterol levels – have been thought to contribute to the increased cardiovascular risk in HIV-infected patients, investigators also have theorized that inflammation may play a role as well. Previous evidence suggesting an association was based on measurements of inflammatory markers like C-reactive protein in the bloodstream, but the current study is the first to provide direct evidence of increased inflammation in the arterial walls of patients with HIV.

The investigators, including Ahmed Tawakol, MD, co-director of the MGH Cardiac MR-PET-CT Program, analyzed the results of PET and CT scans of 81 participants: 27 HIV-infected individuals without known , all receiving antiretroviral therapy; 27 non-infected controls without atherosclerosis, matched with the HIV group in terms of age, gender and traditional cardiovascular risk factors; and 27 non-infected controls known to have atherosclerosis, matched by gender with the HIV group. All of the PET scans used a radiopharmaceutical called FDG, which accumulates in areas of inflammatory activity. Imaging data for both control groups were selected prospectively from a database of patients who had been scanned for clinical diagnosis of non-HIV related conditions.

The FDG PET scans revealed that levels of inflammation in the aortas of the HIV-infected participants were higher than those seen in control participants without atherosclerosis and were actually comparable to levels seen in control participants with cardiovascular disease. Levels of arterial inflammation in the HIV group were not affected by traditional risk factors or the type of antiviral treatment they received, and increased inflammation was even seen in patients whose viral levels were at undetectable levels. Measurement of circulating inflammatory markers found that levels of soluble CD163, a marker of monocyte activation, were elevated in the HIV group; but no differences were seen in markers of generalized inflammation.

"Activated monocytes – part of the innate – may be attracted to plaque lesions in the , where they become activated macrophages that release substances contributing, over time, to plaque rupture and ," Grinspoon explains. "Activated macrophages also can release chemical signals that attract more monocytes, setting up a vicious cycle. We previously showed that increased CD163 levels were associated with noncalcified plaque, which is more susceptible to rupture. Our new findings that levels of CD163, but not other inflammatory markers, are related to inflammation signified by the uptake of FDG – even among patients without detectible virus – suggest that soluble CD163 could be a useful marker of risk-associated inflammation in HIV patients."

A professor of Medicine at Harvard Medical School, Grinspoon stresses that these results do not imply that modification of traditional risk factors is not important in HIV-infected patients but that nontraditional risk factors such as arterial inflammation should also be considered and potentially targeted by new therapies. While FDG-PET scanning would not be appropriate for mass screening of patients, measurement of inflammatory markers like CD163 levels should be explored. His team is currently investigating whether statin treatment might reduce arterial inflammation among -infected patients, the majority of whom demonstrate only modest increases in cholesterol levels.

"Our data also suggest that targeting monocyte activation may be a unique strategy to reduce arterial inflammation in these patients, have implications about the pathogenesis of cardiovascular disease in other inflammatory conditions, and emphasize a new way to look at risk in such patients," Grinspoon adds.

Explore further: Diabetes drug halts atherosclerosis progression in HIV-infected patients

Related Stories

Diabetes drug halts atherosclerosis progression in HIV-infected patients

March 7, 2012
Treatment with the common diabetes drug metformin appears to prevent progression of coronary atherosclerosis in patients infected with HIV. In a presentation today at the 19th Conference on Retroviruses and Opportunistic ...

Low level HIV in bloodstream not linked with inflammation or death

November 8, 2011
(Medical Xpress) -- Low level HIV viremia – the presence of HIV in the bloodstream at levels undetectable by standard tests – was not associated with increased blood markers of inflammation or coagulation, or with ...

Arthritis sufferers at increased risk of heart disease

August 15, 2011
Rheumatoid arthritis (RA) sufferers are at an increased risk of dying due to cardiovascular disease. A new five year study published in BioMed Central's open access journal Arthritis Research & Therapy showed that the risk ...

Recommended for you

New injectable antiretroviral treatment proved to be as effective as standard oral therapy

August 3, 2017
Intramuscularly administered antiretroviral therapy (ART) may be as effective for HIV treatment as current oral therapies. This is the main conclusion of a Phase II clinical trial carried out by 50 research centers around ...

Research finds home-based kit would increase HIV testing

July 31, 2017
Research led by William Robinson, PhD, Associate Research Professor of Behavioral & Community Health Sciences at LSU Health New Orleans School of Public Health, has found that 86% of heterosexuals who are at high risk for ...

Scientists divulge latest in HIV prevention

July 25, 2017
A far cry from the 1990s "ABC" campaign promoting abstinence and monogamy as HIV protection, scientists reported on new approaches Tuesday allowing people to have all the safe sex they want.

Girl's HIV infection seems under control without AIDS drugs

July 24, 2017
A South African girl born with the AIDS virus has kept her infection suppressed for more than eight years after stopping anti-HIV medicines—more evidence that early treatment can occasionally cause a long remission that, ...

Meds by monthly injection might revolutionize HIV care (Update)

July 24, 2017
Getting a shot of medication to control HIV every month or two instead of having to take pills every day could transform the way the virus is kept at bay.

Candidate AIDS vaccine passes early test

July 24, 2017
The three-decade-old quest for an AIDS vaccine received a shot of hope Monday when developers announced that a prototype triggered the immune system in an early phase of human trials.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.